Kura Oncology stock: UBS reiterates Buy rating, USD 15 target
Published on 11/20/2026 at 22:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUBS maintains its Kura view
- UBS analyst David Dai reiterated a Buy rating and a USD 15.00 price target for Kura Oncology on November 20, 2026.
- Third-quarter revenue reached USD 22.84 million, while the GAAP net loss narrowed year over year.
- Kura Oncology reported commercial and development updates after the quarter ended September 30.
UBS analyst David Dai reiterated a Buy rating and a USD 15.00 price target for Kura Oncology on Friday, November 20, 2026, according to Markets Insider. The recommendation and target were maintained rather than changed.
UBS keeps its valuation view
The UBS action leaves the analyst's published valuation framework unchanged. The report placed the call alongside coverage of other healthcare companies and cited a Strong Buy consensus with an average target of USD 26.39.
Quarterly figures provide context
For the quarter ended September 30, Kura Oncology posted revenue of USD 22.84 million and a GAAP net loss of USD 70.22 million, according to the same report. Revenue was USD 20.75 million a year earlier, while the GAAP net loss was USD 74.12 million.
Kura Oncology stock traded at EUR 6.32 on Lang & Schwarz at 10:19 p.m. CET on Friday, November 20, 2026.
Kura Oncology
- Company: Kura Oncology
- ISIN: US50127T1097
- Ticker: KURA
- Trading venue: Lang & Schwarz
- Quote: EUR 6.32 at 10:19 p.m. CET on November 20, 2026
Broader US equities are covered in the S&P 500 market overview.
